The alert by the World Health Organisation (WHO) over the deaths of 66 Gambian infants, suspected to have been caused by the consumption of contaminated cough syrups made by a Sonepat firm, Maiden Pharmaceuticals, has raised serious questions about the probity of drug manufacturing and regulatory pr